India's Stance On IPRs, Pharma in FTA Will Fosters Growth Of Generic Drug Sector: GTRI
10 months, 1 week ago

India's Stance On IPRs, Pharma in FTA Will Fosters Growth Of Generic Drug Sector: GTRI

ABP News  

India's position on intellectual property rights and pharmaceutical issues in proposed trade agreements strikes a balance between fostering innovation and addressing public health needs. By resisting pressures from developed nations regarding concepts like 'data exclusivity' and 'patent linkage' in free trade agreements, India facilitates greater market access for generic drug manufacturers, leading to a significant reduction in the cost of life-saving medications. Proposed FTA terms from developed nations often encompass TRIPs-plus provisions, encompassing aspects such as data exclusivity, patent term extensions, patent evergreening, expanded patentability criteria, and patent linkage. "India scrutinises patent applications rigorously to avoid evergreening, where minor modifications to existing patents extend monopolies, a practice not explicitly addressed by TRIPs but requiring new inventions for patentability," he said.

History of this topic

Local to global: 14 nations keen to adopt India’s generic pharmacy model
1 month, 1 week ago
Thorny clause in ripening India-European Free Trade Association deal may hit generic drug industry
10 months, 1 week ago
Navigating Legal Challenges In The Development Of The Pharmaceutical Sector In India
10 months, 4 weeks ago
India rejects extending drug patents in EU, UK trade talks
1 year, 6 months ago
India-U.K. FTA will tighten screws on generic drugs: Doctors Without Borders Médecins Sans Frontières
2 years, 1 month ago
Understanding India’s stand on IPR at the WTO
2 years, 6 months ago
Explained | The Indian patent regime and its clash with the U.S. norms
2 years, 6 months ago
[LIVE NOW] Webinar On "Revisiting The Access To Medicine Debate In The COVID-19 Era"-
3 years, 9 months ago

Discover Related